174 related articles for article (PubMed ID: 35870043)
1. Denileukin diftitox-induced systemic capillary leak syndrome with acute kidney injury.
Horino T; Okada D; Inotani S; Nakajima H; Komori M; Terada Y
CEN Case Rep; 2023 Feb; 12(1):63-67. PubMed ID: 35870043
[TBL] [Abstract][Full Text] [Related]
2. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
3. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis.
Avarbock AB; Loren AW; Park JY; Junkins-Hopkins JM; Choi J; Litzky LA; Rook AH
Am J Hematol; 2008 Jul; 83(7):593-5. PubMed ID: 18335564
[TBL] [Abstract][Full Text] [Related]
4. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Olsen E; Duvic M; Frankel A; Kim Y; Martin A; Vonderheid E; Jegasothy B; Wood G; Gordon M; Heald P; Oseroff A; Pinter-Brown L; Bowen G; Kuzel T; Fivenson D; Foss F; Glode M; Molina A; Knobler E; Stewart S; Cooper K; Stevens S; Craig F; Reuben J; Bacha P; Nichols J
J Clin Oncol; 2001 Jan; 19(2):376-88. PubMed ID: 11208829
[TBL] [Abstract][Full Text] [Related]
5. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome.
Lambert M; Launay D; Hachulla E; Morell-Dubois S; Soland V; Queyrel V; Fourrier F; Hatron PY
Crit Care Med; 2008 Jul; 36(7):2184-7. PubMed ID: 18552679
[TBL] [Abstract][Full Text] [Related]
7. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
Kerl K; Prins C; Cerroni L; French LE
Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
[TBL] [Abstract][Full Text] [Related]
8. Optimizing denileukin diftitox (Ontak) therapy.
Duvic M; Talpur R
Future Oncol; 2008 Aug; 4(4):457-69. PubMed ID: 18684057
[TBL] [Abstract][Full Text] [Related]
9. Systemic capillary leak syndrome associated with compartment syndrome and rhabdomyolysis.
Sanghavi R; Aneman A; Parr M; Dunlop L; Champion D
Anaesth Intensive Care; 2006 Jun; 34(3):388-91. PubMed ID: 16802499
[TBL] [Abstract][Full Text] [Related]
10. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.
McCann S; Akilov OE; Geskin L
Clin J Oncol Nurs; 2012 Oct; 16(5):E164-72. PubMed ID: 23022942
[TBL] [Abstract][Full Text] [Related]
12. [Systemic capillary leak syndrome: hypoalbuminemia, hemoconcentration and shock. Presentation of a case].
Muñoz-Guillén NM; León-López R; de la Cal-Ramírez MA; Dueñas-Jurado JM
Semergen; 2014 Mar; 40(2):e33-6. PubMed ID: 23768569
[TBL] [Abstract][Full Text] [Related]
13. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Dang NH; Hagemeister FB; Pro B; McLaughlin P; Romaguera JE; Jones D; Samuels B; Samaniego F; Younes A; Wang M; Goy A; Rodriguez MA; Walker PL; Arredondo Y; Tong AT; Fayad L
J Clin Oncol; 2004 Oct; 22(20):4095-102. PubMed ID: 15353540
[TBL] [Abstract][Full Text] [Related]
15. Systemic capillary leak syndrome associated with a rare abdominal and four-limb compartment syndrome: a case report.
Lamou H; Grassmann JP; Betsch M; Wild M; Hakimi M; Windolf J; Jungbluth P
J Med Case Rep; 2014 Jun; 8():196. PubMed ID: 24934689
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic systemic capillary leak syndrome: a case report.
Lee HY; Shin J; Kim SH; Hwang JH
BMC Nephrol; 2023 Mar; 24(1):72. PubMed ID: 36964483
[TBL] [Abstract][Full Text] [Related]
17. Systemic capillary leak syndrome associated with compartment syndrome.
Matsumura M; Kakuchi Y; Hamano R; Kitajima S; Ueda A; Kawano M; Yamagishi M
Intern Med; 2007; 46(18):1585-7. PubMed ID: 17878647
[TBL] [Abstract][Full Text] [Related]
18. Extensive leukoencephalopathy associated with idiopathic capillary leak syndrome: report of a case with neuropathology.
Ohira J; Yoshimura H; Takanashi M; Yamashita D; Hara S; Ueno Y; Hattori N; Kawamoto M; Kohara N
Neurol Sci; 2021 May; 42(5):2095-2098. PubMed ID: 33411202
[TBL] [Abstract][Full Text] [Related]
19. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides.
Ghori F; Polder KD; Pinter-Brown LC; Hoff AO; Gagel RF; Sherman SI; Duvic M
J Clin Endocrinol Metab; 2006 Jun; 91(6):2205-8. PubMed ID: 16595600
[TBL] [Abstract][Full Text] [Related]
20. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease.
Shaughnessy PJ; Bachier C; Grimley M; Freytes CO; Callander NS; Essell JH; Flomenberg N; Selby G; Lemaistre CF
Biol Blood Marrow Transplant; 2005 Mar; 11(3):188-93. PubMed ID: 15744237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
